関連する実験動画
Updated: Jul 28, 2026

06:32
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
まとめ
最大血管拡張が起こる前に,心筋膜の perfusion が著しく低下することがあります. 静止状態では,心内血管拡張剤のリザーブが,心内血管拡張剤のリザーブとは異なり,冠動脈の低圧で持続する.
科学分野:
- 心血管生理学 心血管の生理学
- 心筋パルフュージョンダイナミクス
- 冠動脈の自己調節が起こります.
背景:
- 冠動脈自己調節の理解は,心筋不全の診断と治療に不可欠です.
- 以前の研究では,冠動脈圧の低下と最大血管拡張の関係が完全に解明されていませんでした.
- 心筋 perfusion reserveの評価は,冠動脈疾患の機能的重要性を評価するために不可欠です.
研究 の 目的:
- 冠動脈動脈圧が低下したときに減少した地域性心筋パルフュージョンが,最大血管拡張を確実に示すかどうかを調査する.
- 冠動脈の自己調節が失敗し,血管拡張剤の準備が枯渇する点を決定する.
- 異なる冠動脈圧下における内心と表心血管拡張器の準備量を比較する.
主な方法:
- 制御された円周動脈動脈動脈圧を持つオープンチェスト型犬モデル.
- 異なる冠動脈圧 (自発的,35 mm Hg,25 mm Hg) で地域性心筋血流量 (流入量) の測定.
- アデノシン誘発性血管拡張中の心筋膜 perfusion の評価,血管拡張器の準備を決定する.
主要な成果:
- 冠動脈圧が35mmHgに低下するにつれて,最大血管拡張の前にさえも,心筋膜の perfusion は著しく減少しました.
- 35mmHgでアデノシン注入中に,流れは増加し,残りの血管拡張剤の準備を示しました.
- 25mmHgでは,フローは大幅に減少し,表心準備が持続する一方で,内心準備は著しく増加せず,疲労を示唆しました.
結論:
- 薬理学的血管拡張剤の準備が尽きる前に,心筋膜 perfusion の有意な減少が発生することがあります.
- 心臓内分泌血管拡張剤の準備は,低血圧で35mmHg未満の冠動脈圧に持続し,低血圧がない場合でも持続することができます.
- これらの条件下では,内心血管拡張器の準備は通常,上心血管拡張器の準備よりも前に枯渇します.
さらに関連する動画
関連する概念動画
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

